HHS Secretary Robert F. Kennedy Jr. Seeks to Ease Restrictions on Certain Peptides

Dr.

She stated that growth hormone-related peptides can help with anti-aging and maintaining body composition when used under medical supervision. BPC-157 has shown potential for tissue repair, stomach ulcer healing, and neuroprotection.

Insulin, a naturally occurring peptide, is sold synthetically to regulate blood glucose levels.

The FDA's reclassification has not reduced demand for these peptides.

Instead, it has led to a market of products labeled for "research use only," which avoids regulatory oversight. This results in uncertain product quality, possible contamination, and risks such as infections, hormone disruption, and skin changes. Dr.

Sue Decotiis stated that there is no clear evidence that the peptides are inherently dangerous when used appropriately. She noted that the main concerns involve sourcing, prescription, and usage, with poor manufacturing or unsupervised use increasing risks significantly. She recommended large-scale, long-term clinical studies to assess safety profiles, dosing, and effects.

Dr. Lisa Cassileth called for more robust studies and long-term evaluation of growth hormone secretagogues like ipamorelin. She explained that growth hormone can accelerate tumor growth and is not recommended for long-term use, and data on secretagogues' safety for extended dosing is needed.

restrictions would not equate to full FDA approval for these peptides.

Most peptides lack FDA approval, partly because many, like insulin and BPC-157, occur naturally and are difficult to patent. Without patents, pharmaceutical companies have little incentive to fund the costly clinical trials required for approval. Dr.

Sue Decotiis said that many peptides are unlikely to receive FDA approval, not due to safety issues, but because producers cannot afford the extensive studies. Dr. Lisa Cassileth indicated that reclassification would integrate peptides into mainstream medical practice, encouraging physician education, research funding, and clinical acceptance.

She added that formal clearance would make physicians more comfortable using these compounds in a safe, structured, and evidence-based manner.

Many peptides are currently available through licensed 503A compounding pharmacies under state oversight, producing sterile, regulated products.

However, access varies by state based on regulatory interpretations. Dr. Lisa Cassileth advised sourcing peptides from licensed pharmacies and obtaining prescriptions from qualified clinicians who understand indications, dosing, and risks.

Self-diagnosis and treatment should be avoided. Dr. Sue Decotiis warned that even safe peptides can mask underlying conditions if not part of a structured, individualized treatment plan. Proper medical oversight is essential for safe and effective outcomes.